Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Florentia Dimitriou

Showing results (21-30 of 56) with videos related to

Pageof 6
Sort By:
Frontiers in Medicine|July 28, 2020
Long-Term Disease Control After Allogeneic Hematopoietic Stem Cell Transplantation in Primary Cutaneous T-Cell Lymphoma; Results From a Single Institution AnalysisFlorentia Dimitriou, Urs Schanz, Gayathri Nair, et al.
Cancers|August 7, 2021
Prediction of Early Response to Immune Checkpoint Inhibition Using FDG-PET/CT in Melanoma PatientsKen Kudura, Florentia Dimitriou, Lucas Basler, et al.
Cancers|July 2, 2021
Frequency, Treatment and Outcome of Immune-Related Toxicities in Patients with Immune-Checkpoint Inhibitors for Advanced Melanoma: Results from an Institutional Database AnalysisFlorentia Dimitriou, Ramon Staeger, Melike Ak, et al.
Cancers|July 9, 2022
Correction: Kudura et al. Prediction of Early Response to Immune Checkpoint Inhibition Using FDG-PET/CT in Melanoma Patients. <i>Cancers</i> 2021, <i>13</i>, 3830Ken Kudura, Florentia Dimitriou, Lucas Basler, et al.
Clinical and Experimental Medicine|October 1, 2024
Immunotherapy response and resistance in patients with advanced uveal melanoma: a retrospective cohort studyAlexander Maurer, Giulio Clerici, Jan A Schaab, et al.
Melanoma Research|February 28, 2018
Sarcoid-like reactions in patients receiving modern melanoma treatmentFlorentia Dimitriou, Anna L Frauchiger, Mirjana Urosevic-Maiwald, et al.
Diagnostics (Basel, Switzerland)|June 2, 2021
Malignancy Rate of Indeterminate Findings on FDG-PET/CT in Cutaneous Melanoma PatientsKen Kudura, Florentia Dimitriou, Daniela Mihic-Probst, et al.
NPJ Precision Oncology|November 19, 2025
Conjunctival melanoma genomic analysis reveals intermediate tumor mutation burden and genomic overlap with cutaneous melanomaFlorentia Dimitriou, Xiaogang Wu, Priyadharsini Nagarajan, et al.
Dermatology (Basel, Switzerland)|February 14, 2022
Radiotherapy as a Treatment Option for Local Disease Control in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg TypeMara Zehnder, Boyko Amarov, André N Abrunhosa-Branquinho, et al.
European Journal of Cancer (Oxford, England : 1990)|January 7, 2024
Seasonal patterns of toxicity in melanoma patients treated with combination anti-PD-1 and anti-CTLA-4 immunotherapyAljosja Rogiers, Florentia Dimitriou, Irene Lobon, et al.
Pageof 6

Showing results (21-30 of 56) with videos related to

Sort By:
Pageof 6
Frontiers in Medicine|July 28, 2020
Long-Term Disease Control After Allogeneic Hematopoietic Stem Cell Transplantation in Primary Cutaneous T-Cell Lymphoma; Results From a Single Institution AnalysisFlorentia Dimitriou, Urs Schanz, Gayathri Nair, et al.
Cancers|August 7, 2021
Prediction of Early Response to Immune Checkpoint Inhibition Using FDG-PET/CT in Melanoma PatientsKen Kudura, Florentia Dimitriou, Lucas Basler, et al.
Cancers|July 2, 2021
Frequency, Treatment and Outcome of Immune-Related Toxicities in Patients with Immune-Checkpoint Inhibitors for Advanced Melanoma: Results from an Institutional Database AnalysisFlorentia Dimitriou, Ramon Staeger, Melike Ak, et al.
Cancers|July 9, 2022
Correction: Kudura et al. Prediction of Early Response to Immune Checkpoint Inhibition Using FDG-PET/CT in Melanoma Patients. <i>Cancers</i> 2021, <i>13</i>, 3830Ken Kudura, Florentia Dimitriou, Lucas Basler, et al.
Clinical and Experimental Medicine|October 1, 2024
Immunotherapy response and resistance in patients with advanced uveal melanoma: a retrospective cohort studyAlexander Maurer, Giulio Clerici, Jan A Schaab, et al.
Melanoma Research|February 28, 2018
Sarcoid-like reactions in patients receiving modern melanoma treatmentFlorentia Dimitriou, Anna L Frauchiger, Mirjana Urosevic-Maiwald, et al.
Diagnostics (Basel, Switzerland)|June 2, 2021
Malignancy Rate of Indeterminate Findings on FDG-PET/CT in Cutaneous Melanoma PatientsKen Kudura, Florentia Dimitriou, Daniela Mihic-Probst, et al.
NPJ Precision Oncology|November 19, 2025
Conjunctival melanoma genomic analysis reveals intermediate tumor mutation burden and genomic overlap with cutaneous melanomaFlorentia Dimitriou, Xiaogang Wu, Priyadharsini Nagarajan, et al.
Dermatology (Basel, Switzerland)|February 14, 2022
Radiotherapy as a Treatment Option for Local Disease Control in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg TypeMara Zehnder, Boyko Amarov, André N Abrunhosa-Branquinho, et al.
European Journal of Cancer (Oxford, England : 1990)|January 7, 2024
Seasonal patterns of toxicity in melanoma patients treated with combination anti-PD-1 and anti-CTLA-4 immunotherapyAljosja Rogiers, Florentia Dimitriou, Irene Lobon, et al.
Pageof 6